Clinical trial · Observational
Melanoma Biomarker Study
CXCL1 Biomarker Study in Metastatic Melanoma
NCT00348088CI-TRIAL-00008667completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to measure the level of a specific protein, CXCL1, in the blood of patients with untreated, metastatic (Stage IV) melanoma. These levels will be compared to blood levels in normal controls. If the levels are elevated in metastatic melanoma, further studies to determine if this correlates with presence and extent of disease will be pursued.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Observational study only
- timeFrame
- May 2006-September 2011
- description
- To determine, via sandwiched ELISA, the presence and level of CXCL1 in the serum of patients with metastatic melanoma and to compare these values with CXCL1 levels in normal controls.
Secondary outcomes (1)
- measure
- Observational study only
- timeFrame
- May 2006-September 2011
- description
- To compare serum CXCL1 levels collected peripherally and centrally, in metastatic melanoma patients and To collect serum samples for future study.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologic diagnosis of melanoma; primary may be cutaneous, mucosal or ocular. 2. Evidence of metastatic disease based on standard AJCC staging. 3. Willing to give written informed consent. 4. Willing and able to comply with protocol procedures. 5. At least 18 years of age. 6. No prior chemotherapy, immunotherapy, or radiotherapy. 7. Are able to safely donate 50 mL of blood. 8. Have a central venous catheter in place (this will not be placed for participation in this trial) Exclusion Criteria: 1. Known diagnosis of a chronic inflammatory disease, ie: Rheumatoid Arthritis, Systemic Sclerosis, Inflammatory bowel disease 2. Known diagnosis of NYHA class 3 or 4 Congestive Heart Failure 3. Are unable to safely donate 50 mL blood 4. Known HIV, Hepatitis B, or Hepatitis C infection. 5. Any malignancy within 5 years, other than melanoma (for patients); Have any malignancy within the past 5 years including melanoma (for normal controls). Basal cell and squamous cell skin cancers are permitted in all participants.
References
Publications (0)
Data not yet available
No reference posted for this study.